Acute myocardial infarction treatment remains constrained by a critical tradeoff between efficacy and safety. Current antiplatelet therapies help prevent clot formation but often increase bleeding risk and require time to reach therapeutic effect, limiting their effectiveness during time-sensitive interventions. APT Therapeutics addresses this challenge through an enzyme-based therapeutic approach that targets platelet activation differently from conventional drugs. Its lead candidate, APT102, works by metabolically depleting extracellular ADP and ATP, which are key drivers of platelet activation. “APT102 is more efficacious as it metabolically depletes both extracellular ADP and ATP,” says Ridong Chen, president. Redefining the Balance between Efficacy and Safety A central limitation of existing therapies is their mechanism of action. Current P2Y12 inhibitors block a single receptor pathway, which can lead to increased bleeding risk and delayed onset when administered orally. APT102 introduces a broader mechanism by targeting multiple platelet activation pathways simultaneously, while maintaining a more favorable safety profile. Unlike receptor-blocking drugs, it does not compromise platelet integrity but instead reduces the availability of activating molecules. Another key distinction lies in its delivery method. As an intravenous enzyme, APT102 becomes effective within minutes, addressing the critical need for immediate intervention in heart attack scenarios. This rapid onset supports improved blood flow restoration during early treatment stages. Addressing Time-Sensitive Clinical Challenges Patients experiencing heart attacks face multiple risks, including clot formation, delayed treatment response, and reperfusion injury following intervention. Existing therapies are often limited by slow absorption and dose-related safety concerns. APT Therapeutics focuses on improving both speed and effectiveness of treatment. By enabling faster antithrombotic action, APT102 supports earlier restoration of blood flow. Its mechanism also contributes to cardioprotection through localized generation of adenosine in cardiac tissue. This localized effect distinguishes it from therapies that increase systemic adenosine levels. By concentrating cardioprotective activity at the site of injury, the approach aims to reduce tissue damage associated with reperfusion. .

What challenges do laboratories face when managing workflows across fragmented systems and increasing testing volumes? Laboratories exist to serve patients and clinicians, delivering timely, accurate insights that support critical care decisions. As testing volumes grow and laboratory environments become more interconnected, managing the flow of orders, specimens, results, and communications through multiple systems has become increasingly challenging. What was once a straightforward process now requires coordination across fragmented tools and touchpoints, often without a single unified view. LIMS IQ is designed to address this shift, acting as the brain at the center of laboratory operations, helping laboratories manage workflows, data, and interactions between patients, clinicians, and internal teams. In practice, that role extends beyond simply handling laboratory operations, shaping patient care through both traditional and modern approaches. By placing customer needs at the center, the platform supports clear communication and coordination among stakeholders in the laboratory environment while enabling laboratories to configure solutions to their specific operational demands. A Reimagined Cloud Brain How has LIMS IQ evolved to support multiple laboratory specialties and integrated operational workflows? “We’re not just managing lab workflows; we are connecting the entire operation to how laboratories serve patients and clinicians,” says Skye Shearer, CEO. This view reflects how the platform has evolved in response to changing laboratory needs. Originally developed as LIMS ABC with a focus on toxicology workflows, the platform was rebranded to LIMS IQ in early 2026. What began as a solution for a specific testing segment has evolved into a comprehensive laboratory system that accommodates multiple specialties, including molecular diagnostics, cytology, chemistry, and next-generation sequencing..

What role does STEAP1 targeting play in advancing CAR-T therapies for solid tumors? PromiCell is advancing STEAP1-based CAR-T therapies for solid tumors in collaboration with Fred Hutchinson Cancer Center (FHCC), positioning its lead programs around a target it believes can open a meaningful new chapter in cell therapy beyond liquid tumors. Its scientific strategy centers on STEAP1-directed CAR-T constructs developed with its research partners. FHCC and Memorial Sloan Kettering Cancer Center were previously involved in the founding of Juno Therapeutics, which contributed to the development of the CAR-T therapy Breyanzi. This work established a proven track record in bringing cell therapies to the clinic. “We envision becoming a premier cell therapy company for solid tumors, advancing innovative technologies while minimizing risk and bringing promising treatments to patients efficiently,” says Miltiadis Sougioultzoglou, CEO. Developing Next-Generation CAR-T Therapies How do next-generation CAR-T constructs address persistence, potency, and tumor escape challenges? PromiCell’s next-generation constructs are designed to enhance persistence and potency while addressing tumor escape, immune evasion and disease relapse that can limit the long-term effectiveness of existing therapies. At the center of its platform is STEAP1, a cell surface protein widely expressed in prostate cancer and several other epithelial malignancies. It views STEAP1 as a potentially enabling target for extending CAR-T therapy into solid tumors, where progress has historically been limited despite strong outcomes in hematologic malignancies. By engineering CAR-T cells that recognize this antigen, PromiCell aims to extend CAR-T therapy beyond hematological cancers..

What challenges do data silos create in cell and gene therapy manufacturing workflows? In Cell and gene therapies (CGT) manufacturing—particularly for autologous therapies where one batch often serves a single patient—on-time delivery and first-time-right execution are critical. L7 Informatics, Inc. is addressing this challenge through a data-first Enterprise Science Platform, L7|ESP. When scientific data is spread across siloed systems, batch review and release are delayed, increasing operational complexity, risk and the time taken for treatment delivery. CGT manufacturing is further constrained by complex QC methods, manual process execution and variability in patient-derived starting material, all of which make scaling operations inherently difficult. L7|ESP, a unified, ontology-driven platform, orchestrates scientific data, workflows and operational processes across the CGT lifecycle. By embedding ontologies at the point of data capture, the platform contextualizes data at source, eliminating the need to assemble it retrospectively across systems and creating a single source of truth. Organizations gain real-time visibility into batch and process performance, facilitating deeper process understanding and faster decision-making. “Rather than layering additional systems into an already fragmented environment, L7|ESP creates a single scientific data fabric that connects people, processes, instruments and systems across the vein-to-vein lifecycle,” says Marcia Blackmoore, chief commercial officer..

Why is measurement integrity critical in regulated life sciences and healthcare operations today? In regulated life science operations, a single weak link in measurement can ripple across an entire workflow. This can compromise batch integrity, invalidate a study, or put patients at risk. Mesa Labs’ Calibration Solutions division focuses on that weak link: the tools and services that turn measurement into defensible evidence. Mesa Labs operates across four divisions: Sterilization and Disinfection Control, Clinical Genomics (Agena Bioscience), Biopharmaceutical Development (Gyros Protein Technologies) and Calibration Solutions. These brands are unified under the common mission of “Protecting the Vulnerable.” Inside Calibration Solutions, that purpose becomes practical by building measurement and monitoring systems that help organizations verify and validate critical conditions, document results and stay audit-ready across manufacturing, clinical care, industrial safety and environmental programs. How does real-time environmental monitoring support compliance and reduce operational risks in GxP environments? For GxP environments, real-time visibility can be the difference between a contained deviation and a costly excursion. Mesa’s Environmental Monitoring solutions serve as the last mile in delivering a unified view of critical assets and environments—from vaccine storage in ultra-low-temperature freezers and cold chain warehouses to autoclaves and sterilization processes that require precise thermal mapping—ensuring continuous assurance of product integrity and compliance. Mesa’s Continuous Environmental Monitoring offering, anchored by the ViewPoint® system, provides real-time, gap-free oversight with configurable excursion alerts across assets, rooms and sites. Through a unified, web-based interface, teams can access live and historical data, generate reports and maintain defensible electronic records. The system is purpose-built to align with FDA 21 CFR Part 11 requirements and ISO 17025 best practices, supporting secure data integrity and audit compliance. VPx sensor technology enables simultaneous monitoring of up to 18 environmental parameters, with deployment options across cloud and on-premises architectures to meet varying IT and regulatory constraints. In the absence of such a system, organizations face fragmented data, delayed excursion detection and elevated risk of batch loss, regulatory observations and audit exposure..